Sign in
NXTC Stock Price, Chart, Stats & News
NextCure, Inc.
Save
NextCure, Inc. (NXTC) does not currently pay a dividend.
18.35M
Market cap
–
Current P/E
–
Forward P/E
NXTC chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -111.28% |
ROE | -152.90% |
D/E | 0.15x |
Interest coverage ratio | – |
NXTC valuation
P/E | – |
P/S | – |
P/B | 1.00x |
P/CF | -0.71x |
P/FCF | -0.54x |
P/OCF | -0.71x |
PEG | -0.07x |
EV multiple | -0.86x |
About
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors.
Similar securities
Based on sector and market capitalization
Report issue